Hormonal
The Russian semaglutide-based drug Velgia® (WRYC12301) demonstrates bioequivalence, high safety, and lack of immunogenicity compared to the reference drug Wegovy® at doses of 0.25 mg and 2.4 mg.
This study confirms that the Russian semaglutide product Velgia® is bioequivalent to the brand-name Wegovy® at both 0.25 mg and 2.4 mg doses. It has a comparable safety profile with mild side effects and no detected immunogenicity (antibody formation). For patients seeking this treatment, this generic option offers the same pharmacokinetic exposure as the reference drug.
In the course of the study, the bioequivalence of the study and reference drugs was confirmed. A high safety profile and absence of immunogenicity were demonstrated for the Russian drug Velgia® (WRYC12301, semaglutide, solution for a subcutaneous administration, JSC Biochemik, Russia) in comparison with the reference drug (semaglutide, solution for a subcutaneous administration, Novo Nordisk A/S, Denmark) in doses of 0.25 mg/dose (0.68 mg/mL) and 2.4 mg/dose (3.2 mg/mL).
Why this rating
The study is a small, open-label, randomized bioequivalence trial (n=60) conducted in a single location, lacking long-term clinical efficacy data on weight loss.
Source
Comparative analysis of pharmacokinetic parameters, bioequivalence, safety, tolerability and immunogenicity of semaglutide-based drug for the treatment of obesity
Ametov As et al. · Pharmacy & Pharmacology · 2025
DOI 10.19163/2307-9266-2024-12-3-231-246
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →